Abbonarsi

Shock complicating type A acute aortic dissection: Clinical correlates, management, and outcomes - 06/06/16

Doi : 10.1016/j.ahj.2016.02.019 
Eduardo Bossone, MD, PhD a, ⁎ , Reed E. Pyeritz, MD, PhD b, Alan C. Braverman, MD c, Mark D. Peterson, MD, PhD d, Marek Ehrlich, MD e, Patrick O'Gara, MD f, Toru Suzuki, MD, PhD g, Santi Trimarchi, MD, PhD h, Dan Gilon, MD i, Kevin Greason, MD j, Nimesh D. Desai, MD k, Daniel G. Montgomery, BS l, Eric M. Isselbacher, MD m, Christoph A. Nienaber, MD n, Kim A. Eagle, MD l
on behalf of

IRAD Investigators

a Cardiology Division, University of Salerno, Salerno, Italy 
b Departments of Medicine and Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 
c Cardiovascular Division, Washington University, St Louis, MO 
d Division of Cardiac Surgery, St Michael's Hospital, Toronto, Ontario, Canada 
e Department of Cardiothoracic Surgery, University of Vienna, Vienna, Austria 
f Department of Cardiology, Brigham & Women's Hospital, Boston, MA 
g Cardiovascular Medicine, University of Tokyo, Tokyo, Japan 
h Thoracic Aortic Research Center, IRCCS Policlinico San Donato, San Donato, Italy 
i Heart Institute, Hadassah Hebrew University Medical Center, Jerusalem, Israel 
j Cardiovascular Surgery Department, Mayo Clinic, Rochester, MN 
k Department of Cardiovascular Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 
l Cardiovascular Center, University of Michigan, Ann Arbor, MI 
m Thoracic Aortic Center, Massachusetts General Hospital, Boston, MA 
n Department of Internal Medicine, University of Rostock, Rostock, Germany 

⁎Reprint request: Eduardo Bossone, MD, PhD, FESC, FCCP, FACC, Cardiology Division, “Cava de' Tirreni and Amalfi Coast” Hospital, Heart Department, University of Salerno—Italy, Via Pr. Amedeo, 36-83023 Lauro (AV), Italy.Cardiology Division, “Cava de' Tirreni and Amalfi Coast” Hospital, Heart Department, University of Salerno—Italy, Via Pr. AmedeoLauro (AV)36-83023Italy

Riassunto

Aims

Shock is among the most dreaded and common complications of type A acute aortic dissection (TAAAD). However, clinical correlates, management, and short- and long-term outcomes of TAAAD patients presenting with shock in real-world clinical practice are not known.

Methods and Results

We evaluated 2,704 patients with TAAAD enrolled in the International Registry of Acute Aortic Dissection between January 1, 1996, and August 18, 2012. On admission, 407 (15.1%) TAAAD patients presented with shock. Most in-hospital complications (coma, myocardial or mesenteric ischemia or infarction, and cardiac tamponade) were more frequent in shock patients. In-hospital mortality was significantly higher in TAAAD patients with than without shock (30.2% vs 23.9%, P=.007), regardless of surgical or medical treatment. Most shock patients underwent surgical repair, with medically managed patients demonstrating older age and more complications at presentation. Estimates using Kaplan-Meier survival analysis indicated that most (89%) TAAAD patients with shock discharged alive from the hospital survived 5years, a rate similar to that of TAAAD patients without shock (82%, P=.609).

Conclusions

Shock occurred in 1 of 7 TAAAD patients and was associated with higher rates of in-hospital adverse events and mortality. However, TAAAD survivors with or without shock showed similar long-term mortality. Successful early and aggressive management of shock in TAAAD patients has the potential for improving long-term survival in this patient population.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Conflict of interest disclosures: None.


© 2016  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 176

P. 93-99 - giugno 2016 Ritorno al numero
Articolo precedente Articolo precedente
  • Low real-world early stent thrombosis rates in ST-elevation myocardial infarction patients and the use of bivalirudin, heparin alone or glycoprotein IIb/IIIa inhibitor treatment: A nationwide Swedish registry report
  • Per Grimfjärd, David Erlinge, Sasha Koul, Bo Lagerqvist, Bodil Svennblad, Christoph Varenhorst, Stefan James
| Articolo seguente Articolo seguente
  • Asymmetric dimethylarginine, related arginine derivatives, and incident atrial fibrillation
  • Renate B. Schnabel, Renke Maas, Na Wang, Xiaoyan Yin, Martin G. Larson, Daniel Levy, Patrick T. Ellinor, Steven A. Lubitz, David D. McManus, Jared W. Magnani, Dorothee Atzler, Rainer H. Böger, Edzard Schwedhelm, Ramachandran S. Vasan, Emelia J. Benjamin

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.